Aspirin decreases the risk of recurrent thrombotic events in patients with coronary artery disease or peripheral artery disease but the risk of recurrent events remains high. Long term dual antiplatelet therapy or the combination of aspirin and warfarin further reduces the risk of recurrent events, but at the cost of increased bleeding and neither of these treatments reduce mortality. The Cardiovascular OutcoMes in People using Anticoagulation StrategieS randomised controlled trial involving 27,395 patients from 602 sites in 33 countries (Poland: 9 sites, 518 patients) tested whether low-dose anticoagulant therapy with the coagulation factor Xa inhibitor rivaroxaban given alone or combined with aspirin reduced thrombotic risk compared with aspirin in patients with apparently stable chronic coronary and/or peripheral artery disease. In patients treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily, compared to aspirin alone, the primary outcome of the composite of cardiovascular death, stroke, or myocardial infarction was decreased by 24% (hazard ratio, 0.76; 95% confidence interval, 0.66 to 0.86; p<0.001), and mortality by 18% at the cost of a 70% increase in major bleeding but no significant increase in fatal or intracranial bleeding.
Introduction
Cardiovascular (CV) disease affects more than 300 million people and is the leading cause of death worldwide. [1] Life expectancy at birth in Poland was 77.5 years in 2015 which is more than three years shorter than the European Union average. The higher mortality rates in Poland appear to be explained primarily by CV mortality, which remains high despite a reduction in CV disease mortality over the past 10 years. [2, 3] Aspirin is widely used for long-term secondary prevention of CV disease because it reduces major adverse cardiovascular events (MACE) by 19% and mortality by 10%. [4] Several antithrombotic regimens tested as alternatives to aspirin have further reduced non-fatal CV events, but none have significantly reduced mortality. [5, 6] Furthermore, even with antiplatelet drug combinations, patients with a history of myocardial infarction (MI) have substantial residual thrombotic risk. 5 Rivaroxaban is a direct acting oral anticoagulant (DOAC) that targets coagulation factor Xa.
In the Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Syndrome-Thrombolysis in Myocardial Infarction 51 (ATLAS ACS-2 TIMI 51) trial, low dose rivaroxaban (2.5 mg twice daily) compared with placebo on a background of single or dual agent antiplatelet therapy decreased MACE and mortality with an acceptable bleeding profile. [7] The mean duration of treatment in the ATLAS ACS-2 TIMI 51 trial was 13.1 months with a maximum follow up of 31 months.
Building on the findings of the ATLAS ACS-2 TIMI 51 study, the Cardiovascular OutcoMes in People using Anticoagulation StrategieS (COMPASS) trial tested the hypothesis that longterm treatment with rivaroxaban, given alone or in combination with aspirin, would be superior to aspirin for the prevention of MACE, major adverse limb events (MALE) and mortality in patients with apparently stable chronic coronary artery disease (CAD) or peripheral artery disease (PAD). In a second partial factorial design, the COMPASS trial also tested whether pantoprazole, a proton pump inhibitor (PPI), compared with placebo reduced upper gastrointestinal bleeding in patients with stable CAD or PAD who were not already treated with a PPI. [8] The main results of COMPASS demonstrated that the combination of rivaroxaban and aspirin, compared with aspirin alone, reduced the risk of both MACE and mortality, whereas rivaroxaban alone was not superior to aspirin. Pantoprazole compared with placebo did not reduce upper gastrointestinal tract complications, defined as the composite of overt bleeding, upper gastrointestinal bleeding from a gastroduodenal lesion or of unknown origin, occult bleeding, symptomatic gastroduodenal ulcer or ≥5 erosions, upper gastrointestinal obstruction, or perforation. [9] In this paper we consider the potential impact of the combination of rivaroxaban and aspirin on the burden of CV disease in Poland. The specific objectives of this paper are: to 1) review the burden of CV disease in Poland; 2) summarize the new evidence from the COMPASS trial concerning the efficacy and safety of the combination of rivaroxaban and aspirin for long-term prevention of MACE in patients with chronic CAD or PAD; and 3) provide practical information on managing patients with CAD or PAD in Poland in light of these results.
Burden of CV disease in Poland
CV disease was the cause of an estimated 384500 years lived with disability and 182000 deaths in Poland in 2016. [10, 11] The introduction in Poland of a national public health program in the 1990s, and a corresponding increase in the number of cardiology units and angioplasty procedures have been associated with a decrease in mortality from CV disease Table 1 .
Design of the COMPASS trial
COMPASS was a multicentre double-blind, double dummy, superiority trial which involved patients with a history of apparently stable chronic atherosclerotic vascular disease. [16] Patients were eligible if they had a history of CAD and/or PAD. The definitions of CAD and PAD, as well as inclusion and exclusion criteria, are shown in Table 2 . Eligible patients were randomised to the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily, rivaroxaban 5 mg twice daily (and placebo aspirin), or aspirin 100 mg once daily (and placebo rivaroxaban). Rivaroxaban 5 mg twice daily also reduced MACE and increased bleeding, but did not significantly reduce mortality. [7] The primary outcome of COMPASS was the composite of CV death, stroke, and MI. The secondary outcomes were 1) ischemic stroke, MI, acute limb ischemia (ALI), or death from coronary heart disease; 2) ischemic stroke, MI, ALI, or CV death; 3) death from any cause. bleeding into a surgical site requiring reoperation, and bleeding that led to hospitalization. [16, 17] The net clinical benefit outcome was a composite of the primary outcome, fatal bleeding, or symptomatic bleeding into a critical organ.
MALE was defined as ALI (limb-threatening ischemia which is
27395 patients from 602 centres in 33 countries, including 518 patients from 9 sites in Poland, were randomised to one of the three intervention arms in a 1:1:1 ratio. Prior to randomisation, potentially eligible subjects had to successfully complete a 30-day run-in phase during which they were adherent to aspirin and rivaroxaban placebo at least 80% of the time.
At baseline, the median age of participants was 68.2 years, 22% were female, 75% had a history of hypertension, 38% had a history of diabetes, 3.8% had a prior stroke, 62% had a previous MI. A high proportion of patients enrolled in the trial were receiving other proven secondary prevention therapies. Lipid-lowering agents were used in 90% of patients, angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker in 71%, betablockers in 70%, and diuretics in 29%. The patients included in COMPASS are comparable to those enrolled in prior trials testing alternatives to aspirin for long-term prevention of CV events. There was no significant increase in fatal or critical organ bleeding, and the combination produced a significant net clinical benefit (4.7% versus 5.9%; HR, 0.80; 95% CI, 0.70 to 0.91; p<0.001). [8, 18, 19] There was no significant benefit of rivaroxaban alone compared with aspirin.
Results of the COMPASS trial
The effect of the combination of rivaroxaban and aspirin compared with aspirin on the primary outcome was consistent in subgroups defined by age, sex, geographic region, sex, body weight, renal function, and history of CV risk factors. The benefits of rivaroxaban and aspirin were evident in patients who were already treated with lipid lowering, blood pressure lowering, and ACE inhibitor therapy, and in those at low, intermediate and high risk of subsequent CV events. The magnitude of the benefit from rivaroxaban and aspirin appears to be at least comparable to the benefit from other proven secondary prevention therapies such as lipid lowering, blood pressure lowering and ACE inhibitor therapy, as shown in Table 4 .
Results in the subgroups with CAD or PAD
The majority of patients enrolled in COMPASS had CAD (24824 patients [91%]) and 69% of these patients had a history of MI. In patients with CAD, treatment with rivaroxaban and aspirin reduced the risk of the primary outcome by 26%, stroke by 44% and mortality by 23%. Major bleeding increased by 66%, but fatal bleeding, non-fatal symptomatic intracranial haemorrhage, or bleeding into a critical organ were not significantly increased. [19] Consistent benefits of rivaroxaban and aspirin treatment were evident irrespective of whether patients were enrolled <2 years, 2-5 years, or >5 years after previous MI and in those without a history of MI.
A post-hoc analysis suggested that the additional risk of bleeding in the rivaroxaban and aspirin group, compared to aspirin, decreased over time whereas the reduction in the primary outcome was constant.
PAD was present in 7470 patients, of whom 3402 (46%) had intermittent claudication and 
Highest risk patients
The greatest absolute benefit of rivaroxaban and aspirin was seen in patients who were at highest risk of MACE, such as patients with polyvascular disease, and those with diabetes mellitus, heart failure (HF), or chronic kidney disease (CKD). equates to a number needed to treat of 42. [27] Patients with CKD (defined as CKD stage 3 or higher, estimated glomerular filtration rate
[eGFR] <60 mL/min), compared to those without CKD, had a higher risk of MACE when treated with aspirin alone (8.4% versus 4.6%). Treatment with rivaroxaban and aspirin, compared to aspirin alone, produced a consistent relative risk reduction in MACE, and the ARR in MACE was larger in patients with CKD (1.9%) than in those without CKD (1.1%).
The larger ARR in MACE with the combination of rivaroxaban and aspirin, compared with aspirin alone, was evident in patients with polyvascular disease, diabetes mellitus, HF, or CKD because these subgroups have a higher baseline risk of MACE than patients without these features.
Graft failure after coronary artery bypass graft
Aspirin reduces the risk of graft failure and MACE in patients who have had a coronary artery bypass graft (CABG), but is only modestly effective. Hypothesising that the addition of rivaroxaban to aspirin reduces the risk of graft failure and MACE, 1448 patients who had CABG surgery within the previous 4 to 14 days were randomised to the COMPASS trial and had CABG graft patency evaluated with a computed tomography angiogram one year after surgery. 
How do the results of the COMPASS trial add to prior knowledge?
The results from the COMPASS trial show, for the first time, that long term antithrombotic therapy with the combination of an antiplatelet and an anticoagulant in patients with CAD and PAD produces significant reductions in both morbidity and mortality. These benefits were achieved in apparently stable patients already well treated with proven secondary 
Practical implications of COMPASS for countries with high CV disease burden such as Poland
In countries like Poland, where the CV disease morbidity and mortality is very high, the benefits of rivaroxaban 2.5 mg twice daily and aspirin treatment for patients and potential cost-effectiveness when taking into account the lifelong risk is likely to be particularly pronounced. [29] While the specific pharmacoeconomic analysis for Poland is awaited the results in high risk patients suggest that the COMPASS treatment strategy may be In whom should the COMPASS treatment be avoided?
Rivaroxaban and aspirin treatment should be avoided in patients who cannot tolerate or have a contraindication to aspirin or rivaroxaban, have an unacceptable bleeding risk, or who require long term dual antiplatelet therapy. Bleeding in patients who take antithrombotic therapy is associated with an increased risk of subsequent CV events. [35] 
Aspirin dose in COMPASS regimen
An issue raised in the discussions of COMPASS trial is that aspirin 100mg once daily was used in combination with rivaroxaban 2.5 mg twice daily. In Poland the typical dose of aspirin used is 75mg once daily. Taking into account the pharmacokinetics of aspirin, and the results of previous randomized trials evaluating different doses of aspirin, a 75 mg dose of aspirin can be used instead of 100 mg. [36] Rivaroxaban: management of bleeding 
Rivaroxaban: perioperative interruption
The time for offset of the anticoagulant effects of rivaroxaban 2.5 mg twice daily is likely shorter than for rivaroxaban 20 mg once daily (because at lower doses rivaroxaban have a shorter half-life) and peak drug levels are much lower. For patients who take rivaroxaban 20 mg daily and have creatinine clearance (CrCl) ≥30 mL/min, the last dose of rivaroxaban should be taken no less than 48 hours prior to surgery which has a low bleeding risk, or no less than 72 hours prior surgery which has a high bleeding risk. For patients with CrCl 15 to 29.9 mL/min, the last dose of rivaroxaban should be taken no less than 72 hours prior to surgery which has a low bleeding risk, or no less than 96 hours prior to surgery which has a high bleeding risk. [37] A similar approach is reasonable for patients treated with the combination of rivaroxaban 2.5 mg twice daily and aspirin, although it may be overly conservative as taking the last dose of rivaroxaban 24 hours prior to most types of surgery is likely to provide enough time for offset of the effect of the low doses of rivaroxaban tested in COMPASS.
Conclusion
The COMPASS trial supports the efficacy of low dose rivaroxaban and aspirin for secondary prevention in patients with sable CAD or PAD. The reduction in MACE, with consistent reductions in the individual components of CV death, stroke, and MI, as well as reductions in MALE and overall mortality have not been previously demonstrated with long term antithrombotic therapies. Despite an increase in major bleeding with rivaroxaban and aspirin treatment, there is no significant increase in fatal or intracranial bleeding and the net clinical benefit is in favour of rivaroxaban and aspirin treatment. The benefit of rivaroxaban and aspirin treatment appears to be of at least similar magnitude to other proven secondary prevention therapies. The patients with CAD or PAD who will benefit most from this new strategy are those with polyvascular disease, mild or moderate HF, diabetes, or CKD.
Clinicians in Poland now have rivaroxaban 2.5 mg tablets available to use in combination with aspirin. This new strategy has the potential to substantially reduce the risk of MACE, MALE and mortality in Poland.
